Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

OGT Appoints Dr Bob Holland as CMO

Published: Monday, October 21, 2013
Last Updated: Monday, October 21, 2013
Bookmark and Share
Company strengthens focus on cancer biomarkers.

Oxford Gene Technology (OGT) has announced the appointment of Dr Bob Holland as Chief Medical Officer.

Dr Holland (57), is an expert in biomarker-driven drug development. He has an impressive clinical track record with over 25 years’ experience in the pharmaceutical industry, where he has contributed to the development of significant medicines in neuroscience and oncology.

His long-standing interest in biomarkers led to the creation of an entirely new division at AstraZeneca - Personalized Healthcare & Biomarkers - which is dedicated to the application of molecular biology and imaging techniques to improve the discovery and development of new drugs.

As VP and Head of this division, Dr Holland was instrumental in the generation of a pipeline in which 14 developmental drug programmes were matched with potential companion diagnostic tests.

Dr Holland will add considerably to OGT’s expertise in cancer profiling and biomarker development. He will lead in clinical matters across the range of OGT’s business, working with the R&D and commercial teams to design and implement clinical development programmes to expand OGT’s next generation sequencing and microarray cancer profiling solutions and advanced biomarker programmes in prostate and colorectal cancer.

Commenting on his appointment, Dr Holland said, “The development and commercialization of biomarkers to aid diagnosis and to personalize treatment, particularly in oncology, is something that I have had a continued and unwavering interest in for many years. OGT is at the forefront of this area of medicine and I look forward to joining the team to take the Company’s innovative genomic solutions through to the clinic.”

Dr Mike Evans, CEO, OGT said, “At OGT, we believe in finding the right people with the right expertise to spearhead our business. Bob is an expert in the clinical development of cancer biomarkers, which is a great fit with our strategic aims. His experience will help further OGT’s position in these areas. We are pleased to have Bob on board to help guide our expansion of the range of clinical genomic products and services across the diagnostic pathway.”

The appointment of Dr Holland is another key step in OGT’s commitment to tackle cancer through the development of innovative profiling and diagnosis tools. In May, OGT launched a 58-gene solid tumour profiling next-generation sequencing service to advance vital research into personalized cancer care for breast, prostate, ovarian, lung and colorectal cancer.

In March, the Company was granted a license by The Institute of Cancer Research to develop and commercialize a new panel of diagnostic and prognostic microRNA markers for prostate cancer, and in February it signed an agreement with the Cancer Cytogenomics Microarray Consortium (CCMC) to design a whole genome, cancer-specific microarray which was launched in August.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

OGT’s Popular ESHG Workshop Free to View Online
Learn about the next generation of microarrays in one of the best attended workshops of the conference.
Friday, July 17, 2015
OGT Signs License with Wellcome Trust Sanger Institute
OGT will use novel data on developmental disorders to advance microarray and NGS products for accurate and cost effective identification of rare diseases.
Saturday, April 04, 2015
Oxford Gene Technology Awarded £1.2m Genomics England Contract
Next Generation Sequencing analysis software will support 100,000 Genomes Project by providing intuitive reports for clinical interpretation.
Monday, March 16, 2015
The Role of NGS in Stratified Cancer Medicine
Clinical Scientists reveal the promise and considerations for next generation sequencing in stratified cancer medicine.
Thursday, March 05, 2015
OGT Announces Operational and Financial Highlights for FY 2014
OGT’s molecular genetics business delivers 54% growth in commercial revenues to £11.9m.
Tuesday, December 09, 2014
Pieces of the Puzzle - A Multi-method Approach to Tumour Profiling
OGT workshop provides insight on using complementary genomic technologies.
Friday, November 07, 2014
OGT Initiates Clinical Trial of New Array-Based NIPT
Proprietary microarray technology will be fast, cost-effective, and will enable clinical laboratories to offer NIPT in-house.
Tuesday, November 04, 2014
An Integrated Approach to Clinical Genetics Research
OGT’s new whitepaper explores the next stage of molecular testing.
Wednesday, April 09, 2014
OGT Announces Acquisition of Cytocell Ltd
Company expands leadership in genomic medicine.
Thursday, March 06, 2014
Oxford Gene Technology Expands Leadership in Genomic Medicine
The Company today announced the acquisition of Cambridge-based Cytocell Limited.
Tuesday, March 04, 2014
OGT Strengthens Focus on Cancer Biomarkers
Oxford Gene Technology announce the appointment of Dr Bob Holland as Chief Medical Officer.
Monday, October 21, 2013
OGT Awarded Best Medtech Dealmaker by Oxford Bioscience Network
Award recognizes OGT’s collaboration with Birmingham and Salisbury NHS Regional Genetics Laboratories.
Wednesday, October 09, 2013
OGT to Share Strategies for Reliable NGS Panel Assays
Live webinar will focus on enhanced bait design.
Thursday, September 19, 2013
Exploring the Next Generation of Cancer Genomics at BSGM
aCGH to NGS: OGT invites University of Oxford Professor to present latest research.
Thursday, September 12, 2013
A Snapshot of the NGS Market — User Views
Oxford Gene Technology has released the results from a recent survey of researchers using next generation sequencing.
Wednesday, August 21, 2013
Scientific News
RNAi Screening Trends
Understand current trends and learn which application areas are expected to gain in popularity over the next few years.
Diagnostic Test Developed for Enterovirus D68
researchers at Washington University School of Medicine in St. Louis have developed a diagnostic test to quickly detect enterovirus D68 (EV-D68), a respiratory virus that caused unusually severe illness in children last year.
How a Kernel Got Naked and Corn Became King
Ten thousand years ago, a golden grain got naked, brought people together and grew to become one of the top agricultural commodities on the planet.
Sweet Revenge Against Superbugs
A special type of synthetic sugar could be the latest weapon in the fight against superbugs.
New Material Opens Possibilities for Super-Long-Acting Pills
A pH-responsive polymer gel could create swallow able devices, including capsules for ultra-long drug delivery.
How To Keep Your Rice Arsenic-Free
Researchers at Queen’s University Belfast have made a breakthrough in discovering how to lower worrying levels of arsenic in rice that is eaten all over the world.
New Tool For Investigating RNA Gone Awry
A new technology – called “Sticky-flares” – developed by nanomedicine experts at Northwestern University offers the first real-time method to track and observe the dynamics of RNA distribution as it is transported inside living cells.
Computer Model Could Explain how Simple Molecules Took First Step Toward Life
Two Brookhaven researchers developed theoretical model to explain the origins of self-replicating molecules.
New Tech Enables Epigenomic Analysis with a Mere 100 Cells
A new technology that will dramatically enhance investigations of epigenomes, the machinery that turns on and off genes and a very prominent field of study in diseases such as stem cell differentiation, inflammation and cancer has been developed by researchers at Virginia Tech.
Access Denied: Leukemia Thwarted by Cutting Off Link to Environmental Support
A new study reveals a protein’s critical – and previously unknown -- role in the development and progression of acute myeloid leukemia (AML), a fast-growing and extremely difficult-to-treat blood cancer.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!